Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
نویسندگان
چکیده
Purpose of the study Atazanavir is a good but expensive regimen in resource limited settings (RLS). A previous HIV-NAT study showed that a low dose of ATV/r 200/100mg once daily (QD) provided adequate atazanavir plasma concentrations in HIV-infected Thai adults. Reducing the dose would make atazanavir more accessible to those patients in need in RLS. We aimed to evaluate long term efficacy of lower dose ATV/r 200/100 mg in HIV-infected Thai adults.
منابع مشابه
Pharmacokinetics of Atazanavir in Ritonavir-boosted Combination in Asian Healthy Volunteers: Comparisons between the Standard and Reduced Doses of Both Agents
Atazanavir/ritonavir (ATV/r) 200/100 mg once-daily (OD) has been shown comparable in drug exposure to the standard dose in Asian study. We explored the pharmacokinetic profiles of the boosting effect of ritonavir at 50 mg to either atazanavir 300 or 200 mg in 32 adult Thai healthy volunteers. The geometric means (GM) of ATV AUC0-24 were 40.66, 25.50 and 24.97 mg-h/L and Cmin were 0.53, 0.27 and...
متن کاملPharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
BACKGROUND Atazanavir/ritonavir (ATV/r) is a boosted protease inhibitor recommended to minimize the risk of mother-to-child HIV-1 transmission (MTCT). We aimed to assess the pharmacokinetics, safety and efficacy of ATV/r in HIV-1-infected pregnant women and their neonates. METHODS A multicentre, cross-sectional, non-interventional cohort of HIV-1-infected pregnant women receiving ATV/r (300/1...
متن کاملSLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients
Background Atazanavir (ATV) is administered at a dose of 300 mg boosted with 100 mg of ritonavir once daily (boosted). However, in the clinical setting use of unboosted ATV can be warranted. Although plasma concentrations are used clinically as a marker of drug exposure, ATV predominantly acts within HIV infected cells and therefore intracellular concentrations may better correlate with therape...
متن کاملEffect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
Mycobacterium tuberculosis is a concern in patients with human immunodeficiency virus (HIV) infection. Rifampin (RIF), an agent used against M. tuberculosis, is contraindicated with most HIV protease inhibitors. Atazanavir (ATV) has clinical efficacy comparable to a standard of care regimen in naive patients and, when dosed with low-dose ritonavir (RTV), also in treatment-experienced patients. ...
متن کاملLong-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study
BACKGROUND Boosted protease inhibitors (PIs), including ritonavir-boosted atazanavir (ATV/r), are a recommended option for the initial treatment of HIV-1 infection based upon clinical trial data; however, long-term real-life clinical data are limited. OBJECTIVE We evaluated the long-term use of ATV/r as a component of antiretroviral combination therapy in the real-life setting in the REMAIN s...
متن کامل